ASCO 2018 - Results from #14

Viewing 21-26 of 26 articles

ASCO 2018: SPIRE: A Phase 1b/Randomized 2a Open Label Clinical Trial Combining Guadecitabine (SGI-110) with Cisplatin and Gemcitabine Chemotherapy for Solid Malignancies Including Bladder Cancer

ASCO 2018: Atezolizumab in First-Line Cisplatin-Ineligible or Platinum Treated Locally Advanced or Metastatic Urothelial Cancer: Long-Term Efficacy from Phase 2 Study IMvigor210

ASCO 2018: BMS-986205, an IDO1 Inhibitor, in Combination with Nivolumab: Updated Safety Across all Tumor Cohorts and Efficacy in Patients with Advanced Bladder Cancer

ASCO 2018: Apache: Open Label, Randomized, Phase 2 Study of Durvalumab, Alone or in Combination with Tremelimumab, in Patients with Advanced Germ Cell Tumors: Results at the End of First Stage

ASCO 2018: Pembrolizumab versus Investigator’s Choice (Paclitaxel, Docetaxel, or Vinflunine) in Recurrent, Advanced Urothelial Cancer: 2-Year Follow-Up from KEYNOTE-045 Trial

ASCO 2018: A Subgroup Analysis of the East Asia Population in RANGE

ASCO 2018: Atezolizumab in Special Populations: Analyses from an Expanded Access Program in Platinum-Treated Locally Advanced or Metastatic Urothelial Carcinoma

ASCO 2018: First-Line Pembrolizumab in Cisplatin Ineligible Advanced Urothelial Cancer-KEYNOTE-052

ASCO 2018: Clinical Complete Response to Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer

ASCO 2018: Bladder-Sparing Strategies in Bladder Cancer

ASCO 2018: Challenges of Perioperative Systemic Therapy of Localized Urothelial Cancer

ASCO 2018: Nuances of Surgical Management of Localized/Locally Advanced Urothelial Cancer

1
2